An injection that reprograms the body's own killer cells — no laboratory detour needed

Powerful cell therapies for cancer usually begin the same slow way: take a patient's immune cells out, reprogram them in a laboratory, grow them, ship them back. Engineers at MIT, led by Daniel Anderson with lead author Yuang Chen, have shown in mice that the detour may be skippable. Their lipid nanoparticles — tiny fat bubbles carrying messenger RNA instructions — travel straight to natural killer (NK) cells inside the body and reprogram about 80% of them to hunt diseased T cells. In an aggressive melanoma model, three of five treated mice went into complete remission; in mice carrying human immune cells, T-cell lymphoma tumours were eradicated after five injections; and a single injection cleared the rogue T cells behind autoimmune hepatitis, letting liver damage heal. The work, published in Nature Biotechnology, is animal research, years from patients — but it points to cell therapy as a simple infusion rather than a bespoke manufacturing odyssey.

SDG 3 · Good health and well-being — Mechanism: tech innovation